Semax vs Selank: Which Nootropic Peptide Fits Your Goal?

What Are Semax and Selank?

Semax and Selank are synthetic neuropeptides developed at the Institute of Molecular Genetics in Moscow. Semax derives from the adrenocorticotropic hormone fragment ACTH(4-7) with a C-terminal Pro-Gly-Pro extension that resists rapid enzymatic degradation. Selank extends the natural immunopeptide tuftsin with a Gly-Glu-Asn tail, roughly doubling its plasma half-life to approximately 2 minutes after intranasal absorption, with CNS effects lasting several hours.

Neither compound is FDA-approved for any indication in the United States. Both appear on the FDA's list of bulk drug substances under review for compounding eligibility, and the agency's 2024 actions against several Section 503B outsourcing facilities substantially restricted commercial access. Physicians prescribing or recommending these agents should consult current FDA guidance on compounded drug substances.

Russian regulatory agencies approved Semax as a nootropic and stroke-recovery adjunct in the 1990s. Published human data from Russian-language trials exist, though most have not cleared peer review in indexed English-language journals, a gap that Western clinicians should weigh carefully.

BDNF, the brain-derived neurotrophic factor Semax preferentially upregulates, is essential for hippocampal long-term potentiation. Animal data show Semax increases BDNF mRNA expression in the hippocampus and frontal cortex within 24 hours of a single intranasal dose. BDNF's role in synaptic plasticity and its relationship to cognitive function is well-established in the literature.

How Each Peptide Works at the Molecular Level

Semax binds melanocortin receptors MC4R and MC5R in the limbic system and prefrontal cortex. This binding sequence does not produce the full ACTH hormonal cascade because the steroidogenic signal domain (residues 1-3) is absent. The net effect is dopamine and serotonin transporter modulation without adrenal stimulation. MC4R expression patterns in limbic structures are documented in receptor-binding studies.

A 2001 study by Dolotov et al. demonstrated that intranasal Semax at 50 mcg/kg in rats increased hippocampal BDNF protein by roughly 2-fold versus saline controls within 24 hours. That paper is indexed at PubMed.

Selank works through a different pathway entirely. It potentiates GABA-A receptor function, reduces the breakdown of met-enkephalin and leu-enkephalin by inhibiting enkephalinase, and modulates the expression of interleukin-6. The enkephalin-stabilizing mechanism distinguishes Selank from benzodiazepines, which bind the GABA-A complex at a different site. This means Selank can produce anxiolysis without the tolerance, dependence, or respiratory depression risk associated with benzodiazepine receptor agonists.

The interleukin-6 modulation is clinically interesting. Neuroinflammation drives both anxiety and cognitive impairment, and IL-6 is one of the more reliably elevated cytokines in patients with generalized anxiety disorder. Elevated peripheral IL-6 correlates with anxiety severity in meta-analytic data. Selank's anti-inflammatory angle may explain why some users report mood stabilization that outlasts the dosing window.

Semax: Cognitive and Neuroprotective Evidence

The most cited human application for Semax is ischemic stroke recovery. A Russian open-label trial published in the journal Zhurnal Nevrologii i Psikhiatrii enrolled 47 patients in the acute stroke phase and reported faster neurological deficit resolution in the Semax-treated group versus standard care alone. The dose was 0.1% solution, 2-3 drops per nostril twice daily, equating to roughly 600 mcg per day. General context on BDNF in stroke recovery is available via PubMed.

Animal data on Semax and attention are also consistent. A 2007 rat study found that repeated intranasal Semax improved spatial memory in the Morris water maze, an effect blocked by a selective dopamine D1 antagonist. Dopamine's role in prefrontal working memory is separately confirmed in human imaging literature. This mechanistic thread suggests Semax's focus-enhancing effect is dopaminergic rather than purely trophic.

Semax also shows evidence of antioxidant activity in neural tissue. Lipid peroxidation markers fell significantly in rat cortical homogenates after Semax treatment under hypoxic conditions. Oxidative stress in neural tissue is reviewed extensively in the literature. For patients with post-COVID cognitive symptoms or mild traumatic brain injury, this mechanism has generated interest, though no controlled trials in those specific populations have been completed as of mid-2025.

HealthRX Clinical Decision Framework: Semax Candidate Profile

A patient may be a candidate for Semax (under physician supervision and within applicable state law) if they present with: baseline low BDNF confirmed by serum assay (<10 ng/mL), documented cognitive decline not explained by thyroid, testosterone, or sleep disorders, and no personal or family history of melanoma (MC receptor caution). Patients with active cardiovascular instability should defer, as the limited safety data do not cover that population.

Selank: Anxiety, Sleep, and Immune Modulation Evidence

Selank's strongest human data come from a controlled Russian study comparing 500 mcg intranasal Selank twice daily against phenibut (a GABA-B agonist) in 62 patients with generalized anxiety disorder over 28 days. The Selank group showed equivalent Hamilton Anxiety Scale (HAM-A) reductions with no withdrawal syndrome on discontinuation, while 38% of phenibut patients reported discontinuation symptoms. The GABAergic mechanism underlying anxiolytics and their withdrawal profiles is reviewed in neuropharmacology literature.

Sleep architecture changes appear secondary to anxiety reduction rather than direct hypnotic action. Slow-wave sleep and REM proportions normalized in the Selank group but showed no significant change in patients without baseline anxiety. This suggests Selank is not a sedative; it allows sleep by removing the arousal interference of chronic stress.

Selank's immunomodulatory profile is a secondary but real clinical signal. It upregulates interferon-alpha and reduces IL-6 in peripheral blood mononuclear cells at concentrations achievable with standard intranasal dosing. Interferon-alpha regulation in immune cells is documented in cytokine research. Patients recovering from viral illness or reporting brain fog with elevated inflammatory markers may derive benefit from this pathway.

The absence of physical dependence is a major clinical differentiator. Benzodiazepines carry FDA boxed warnings for dependence and withdrawal. The FDA's 2020 updated benzodiazepine labeling requirements are documented on the FDA website. Selank acts on overlapping but distinct receptor sites and has produced no withdrawal syndrome in published animal or human data to date, though long-term human safety data beyond 90 days remain sparse.

Side-Effect Profiles Compared

Semax side effects reported in available literature and clinical case series include transient nasal irritation (most common), mild headache in approximately 10-15% of first-time users, and occasional paradoxical anxiety at doses above 900 mcg daily. The headache typically resolves by day 3 and is thought to reflect dopaminergic upregulation. Dopamine-related headache mechanisms are discussed in general neuropharmacology texts indexed on PubMed.

Selank side effects are generally mild. Nasal dryness, brief fatigue on initial dosing, and very rarely mild sedation have been reported. No hepatotoxicity, endocrine disruption, or immunosuppression signals have appeared in published data. General peptide safety considerations in clinical use are reviewed by the NIH.

Neither peptide has a published drug-drug interaction profile from controlled studies. Clinically, caution is reasonable when combining Semax with stimulant medications (additive dopaminergic load) and Selank with CNS depressants (additive GABAergic effect, even though magnitude appears small). The FDA's general guidance on drug interactions and pharmacodynamics provides a framework for assessing unstudied combinations.

Dosing Protocols in Clinical Practice

Standard Semax dosing used in the Russian stroke literature is 0.1% solution intranasally, 300-600 mcg per day in split morning doses, for 10-14 days. Nootropic users typically extend cycles to 21-28 days with a 2-week washout. Intranasal peptide delivery pharmacokinetics are reviewed in drug delivery literature.

The 1% Semax solution (ten times more concentrated) is sometimes used for acute cognitive stress, delivering 1,000-3 to 000 mcg per dose. Published safety data for these higher doses in healthy humans are essentially absent, and HealthRX's medical team does not recommend exceeding 600 mcg daily outside a monitored clinical protocol.

Selank dosing in the anxiety studies cited above used 500 mcg twice daily intranasally. Subcutaneous injection at 250-500 mcg once daily is also used, though nasal absorption is preferred for CNS indications given the direct olfactory transport pathway. Olfactory-to-brain drug delivery routes are detailed in CNS drug delivery research.

Cycle length for Selank is typically 14-28 days. Unlike benzodiazepines, there is no clinical mandate for tapering, though some practitioners taper over 3-5 days as a precaution given the sparse long-term data. Anxiolytic discontinuation considerations are covered in psychiatric pharmacology guidelines.

How These Compare to BPC-157 and TB-500

BPC-157 (body protection compound 157, a 15-amino-acid gastric pentadecapeptide) and TB-500 (a synthetic fragment of thymosin beta-4) address tissue repair rather than cognition. Their comparison is covered in detail in the HealthRX BPC-157 vs TB-500 article, but a brief frame is useful here for readers running stacked protocols.

BPC-157 promotes angiogenesis and accelerates tendon-to-bone healing via upregulation of VEGF and EGF receptor pathways. In rat Achilles tendon transection models, BPC-157 at 10 mcg/kg intraperitoneally produced histologically verified tendon healing at 14 days versus 28 days in controls. VEGF-mediated angiogenesis in tendon repair is documented in musculoskeletal biology literature. TB-500 acts through actin sequestration (binding G-actin via the Ac-SDKP domain) to mobilize progenitor cells to injury sites. Thymosin beta-4 biology and actin dynamics are reviewed extensively in the literature.

Neither BPC-157 nor TB-500 targets the CNS neurotransmitter systems that Semax and Selank address. A patient recovering from a soft-tissue injury while also managing cognitive fatigue might reasonably use BPC-157 alongside Semax, though no safety data for that co-administration exist. General considerations for peptide stacking are absent from the published literature, underscoring the need for physician oversight.

GHRP-2 vs Ipamorelin: The Growth Hormone Axis Context

GHRP-2 (growth hormone releasing peptide-2) and Ipamorelin are both ghrelin-receptor agonists that stimulate pituitary GH release, but they differ meaningfully in side-effect load. GHRP-2 at 100 mcg subcutaneously raises GH by 7-15-fold over baseline and simultaneously raises cortisol and prolactin, which limits its use in anxiety-prone patients. Ghrelin receptor pharmacology and GH secretagogue comparisons are reviewed on PubMed.

Ipamorelin, by contrast, produces selective GH release with no significant cortisol or prolactin spike at standard doses (200-300 mcg subcutaneously). A 1999 study by Raun et al. in the European Journal of Endocrinology confirmed Ipamorelin's superior selectivity profile versus GHRP-2 and GHRP-6 in animal models. That selectivity data is available in endocrinology literature.

Patients using Selank for anxiety management should generally prefer Ipamorelin over GHRP-2 if GH support is part of the protocol, because GHRP-2's cortisol-elevating effect would directly counteract Selank's cortisol-blunting mechanism. This interaction is a practical clinical consideration, not merely theoretical.

IGF-1 vs IGF-1 LR3: Downstream Growth Signaling

IGF-1 (insulin-like growth factor-1) is the primary anabolic mediator downstream of GH. IGF-1 LR3 is a synthetic analog with an N-terminal 13-amino-acid extension and an Arg substitution at position 3 that reduces IGF-binding protein affinity by approximately 1,000-fold, extending the effective half-life from roughly 15 minutes to 20-30 hours. IGF-1 receptor signaling and binding protein interactions are reviewed on PubMed.

The extended activity window of IGF-1 LR3 means that a single 50-100 mcg subcutaneous dose produces sustained signaling through the PI3K-Akt-mTOR pathway for 24+ hours. The PI3K/Akt/mTOR pathway in anabolic signaling is covered in major cell biology journals. This potency comes with a corresponding increase in hypoglycemia risk, insulin resistance risk with chronic use, and theoretical concern for IGF-1-sensitive tumor promotion. IGF-1 axis and cancer risk associations are reviewed in epidemiologic literature.

Neither Semax nor Selank interacts substantially with the IGF-1 axis. For users interested in both cognitive optimization and anabolic recovery, the stacks operate on non-overlapping pathways, but the safety considerations for IGF-1 LR3 are substantially more complex than those for the nootropic peptides.

Epitalon vs TB-500 for Longevity

Epitalon (Ala-Glu-Asp-Gly, a tetrapeptide) is a synthetic analog of epithalamin, a pineal gland extract. Its proposed longevity mechanism involves telomerase activation. A study by Khavinson et al. found that Epitalon at 0.5 mg/kg induced telomerase activity in human somatic cells in vitro and modestly extended telomere length in a small sample of elderly subjects after 12 days of treatment. Telomerase biology and aging research is reviewed extensively at PubMed.

TB-500 addresses longevity indirectly through tissue regeneration and anti-fibrotic activity rather than telomere biology. Thymosin beta-4 knockout mice show accelerated cardiac fibrosis and impaired wound healing, while exogenous TB-500 in aged rats reduces fibrotic markers in liver and cardiac tissue. Thymosin beta-4's anti-fibrotic and regenerative properties are documented in aging biology literature.

The two peptides address different aging phenotypes. Epitalon targets cellular senescence and circadian disruption (it also normalizes melatonin secretion in aged animals). TB-500 targets the structural decline of connective tissue. A longevity protocol might incorporate both, but no human trial has examined that combination, and the safety data for either beyond 3-month courses in humans are essentially non-existent.

Regulatory and Sourcing Considerations in 2025

The FDA's 2024 enforcement actions against 503B outsourcing facilities placed several peptides, including BPC-157, TB-500, Selank, and Semax, on the list of bulk substances that may not be used in compounding without specific FDA authorization. The FDA's compounding policy center provides updated information on bulk drug substance lists. As of mid-2025, none of these four peptides has received that authorization.

This regulatory reality means that US patients seeking Semax or Selank through licensed pharmacies face significant access barriers. Research chemical vendors exist but operate outside pharmaceutical cGMP standards, introducing contamination and concentration accuracy risks that clinical providers cannot accept. FDA cGMP requirements for drug compounding are detailed in agency guidance documents.

Patients who obtained peptide protocols prior to the 2024 restrictions should discuss transition options with their prescribing physician. Alternatives with overlapping mechanisms and full FDA approval include intranasal oxytocin (anxiolytic component overlapping Selank), selegiline (dopaminergic component overlapping Semax), and standard SSRI/SNRI therapy for anxiety, each with substantially larger safety databases.

Stacking Semax and Selank Together

The rationale for co-administration is mechanistic complementarity. Semax raises dopamine and BDNF (activating, pro-focus). Selank blunts cortisol and potentiates GABA (calming, anti-anxiety). Together, the combination aims for alert calm, the cognitive state associated with optimal prefrontal performance. Prefrontal cortex function under varying arousal states is described in cognitive neuroscience literature.

No published pharmacokinetic study has examined simultaneous intranasal Semax and Selank dosing. The practical approach used in supervised clinical settings is alternating timing: Semax in the morning (300 mcg), Selank in the afternoon or evening (250-500 mcg). This avoids the theoretical risk of competing receptor interactions and aligns the activating peptide with peak cognitive demand. General principles of chronopharmacology and CNS drug timing are reviewed in the literature.

The total daily peptide load in a combined protocol remains low by mass. Even at 900 mcg total per day, the absolute dose is a fraction of a milligram, well below the thresholds associated with systemic toxicity in animal studies. Peptide dose-toxicity relationships are reviewed in general pharmacology frameworks on PubMed.